Exact gatecrashes the liquid biopsy party

It is fair to say that liquid biopsies are having a moment. The past month has seen two pan-cancer blood tests approved in the US and the developer of a third acquired in a multibillion-dollar deal. Now Exact Sciences has posted unexpectedly encouraging data on its own multi-cancer blood test, and has enjoyed a 27% share price jump as a result.